Potassium Phosphate, Tribasic → 6-(1-(2-cyanoethyl)-1H-pyrazol-4-yl)-4-(((3R,4R)-3-ethyl-1-(methylsulfonyl)piperidin-4-yl)amino)pyrrolo[1,2-b]pyridazine-3-carboxamide

HRID 877757

Reaction equation

HRID 877757 reaction equation
Br[C:2]1[CH:3]=[C:4]2[C:9]([NH:10][C@@H:11]3[CH2:16][CH2:15][N:14]([S:17]([CH3:20])(=[O:19])=[O:18])[CH2:13][C@H:12]3[CH2:21][CH3:22])=[C:8]([C:23]([NH2:25])=[O:24])[CH:7]=[N:6][N:5]2[CH:26]=1.CC1(C)C(C)(C)OB([C:35]2[CH:36]=[N:37][N:38]([CH2:40][CH2:41][C:42]#[N:43])[CH:39]=2)O1.P([O-])([O-])([O-])=O.[K+].[K+].[K+]>C1C=CC(P(C2C=CC=CC=2)[C-]2C=CC=C2)=CC=1.C1C=CC(P(C2C=CC=CC=2)[C-]2C=CC=C2)=CC=1.Cl[Pd]Cl.[Fe+2].C(Cl)Cl.O1CCOCC1>[C:42]([CH2:41][CH2:40][N:38]1[CH:39]=[C:35]([C:2]2[CH:3]=[C:4]3[C:9]([NH:10][C@@H:11]4[CH2:16][CH2:15][N:14]([S:17]([CH3:20])(=[O:19])=[O:18])[CH2:13][C@H:12]4[CH2:21][CH3:22])=[C:8]([C:23]([NH2:25])=[O:24])[CH:7]=[N:6][N:5]3[CH:26]=2)[CH:36]=[N:37]1)#[N:43]

Participants

6

Reactant 3

HCID 62657Potassium Phosphate, TribasicHCID 569657334-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole-1-propanenitrileHCID 682911046-bromo-4-(((3R,4R)-3-ethyl-1-(methylsulfonyl)piperidin-4-yl)amino)pyrrolo[1,2-b]pyridazine-3-carboxamide

Product 1

HCID 682907846-(1-(2-cyanoethyl)-1H-pyrazol-4-yl)-4-(((3R,4R)-3-ethyl-1-(methylsulfonyl)piperidin-4-yl)amino)pyrrolo[1,2-b]pyridazine-3-carboxamideYield 56.9%

Reagents, catalysts & solvents 2

HCID 178418807HCID 178418807, compoundCatalystHCID 312751,4-DioxaneSolvent

Conditions

Temperature
100 °C

Procedure

To a vial charged with 6-bromo-4-(((3R,4R)-3-ethyl-1-(methylsulfonyl)piperidin-4-yl)amino) pyrrolo[1,2-b]pyridazine-3-carboxamide (15 mg, 0.034 mmol), 3-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl)propanenitrile (16.68 mg, 0.068 mmol) and PdCl2(dppf)-CH2Cl2 Adduct (3.61 mg, 4.42 μmol) were added 1,4-dioxane (225 μl) and a 2M solution of potassium phosphate (50.6 μl, 0.101 mmol). The suspension was purged with nitrogen for 5 minutes. The vial was sealed and heated at 100° C. for 2 hrs. The reaction mixture was diluted with methanol (10 ml), filtered, and concentrated under reduced pressure. The crude product was purified via preparative HPLC (Column: Waters XBridge C18, 19×200 mm, 5-μm). The collected fractions were combined and dried via centrifugal evaporation, yielding 6-(1-(2-cyanoethyl)-1H-pyrazol-4-yl)-4-(((3R,4R)-3-ethyl-1-(methylsulfonyl)piperidin-4-yl)amino)pyrrolo[1,2-b]pyridazine-3-carboxamide (9.3 mg, 0.019 mmol, 56.9% yield) as a white solid. 1H NMR (500 MHz, 1:1 Chloroform-d/Methanol-d4) δ 8.12 (s, 1H), 7.93 (s, 1H), 7.82 (s, 1H), 7.75 (d, J=1.5 Hz, 1H), 6.91 (d, J=1.0 Hz, 1H), 4.48 (t, J=6.4 Hz, 2H), 4.11 (td, J=8.4, 4.0 Hz, 1H), 3.79-3.61 (m, 2H), 3.25-3.17 (m, 1H), 3.05 (t, J=6.4 Hz, 2H), 2.97-2.85 (m, 4H), 2.43-2.34 (m, 1H), 1.88-1.76 (m, 3H), 1.51-1.40 (m, 1H), 1.04-0.97 (m, 3H). LCMS (Method K) m/z 485.0 ([M+H]+). HPLC (Method F) Rt: 1.14 min.

Workup

  1. customThe suspension was purged with nitrogen for 5 minutes
  2. customThe vial was sealed
  3. additionThe reaction mixture was diluted with methanol (10 ml)
  4. filtrationfiltered
  5. concentrationconcentrated under reduced pressure
  6. customThe crude product was purified via preparative HPLC (Column: Waters XBridge C18, 19×200 mm, 5-μm)
  7. customdried via centrifugal evaporation

Sources & evidence

ORD record
ord-83d8bd8775094ff99710a897992b227b
Source dataset
uspto-grants-2015_03
Patent number
US08987268B2

Linked notes

Loading…